Novel crystalline forms of compounds, and methods for their preparation and use

Novel crystalline forms of (R)-2-(1-(2-(1-hydroxylethyl)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)piperidine-4-yl)acetonitrile address the lack of understanding in crystal forms, offering improved stability and solubility for pharmaceutical use.

JP2024543260APending Publication Date: 2024-11-20E NITIATE BIOPHARMACEUTICALS (HANGZHOU) CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024531270
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-25
Filing Date
2022-11-22
Publication Date
2024-11-20

AI Technical Summary

Technical Problem

Current research lacks understanding of the crystal forms of the compound (R)-2-(1-(2-(1-hydroxylethyl)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)piperidine-4-yl)acetonitrile, which is crucial for predicting and achieving optimal pharmaceutical properties such as stability and solubility.

Method used

Development of novel crystalline forms A, H, S, O, P, Q, and M of the compound, characterized by specific X-ray diffraction peaks and preparation methods involving solvent systems like ethanol, n-heptane, and ethanol-water, ensuring high stability and solubility.

Benefits of technology

The novel crystalline forms exhibit good stability, high solubility, and bioavailability, making them suitable for pharmaceutical applications, particularly in treating allergic reactions and diseases mediated by JAK kinase (JAK1).

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543260000001_ABST
    Figure 2024543260000001_ABST
Patent Text Reader

Abstract

The present invention provides crystalline forms of the compound of formula (I), processes for preparing said crystalline forms, pharmaceutical compositions containing said crystalline forms, and their use in the preparation of medicaments for treating a disease, illness or condition, or therapeutic methods for treating a disease, illness or condition. TIFF2024543260000027.tif31153
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the chemical and pharmaceutical technical field, in particular to a novel crystalline form of a compound, a process for preparing the crystalline form, a pharmaceutical composition containing said crystalline form, and the use of said crystalline form and pharmaceutical composition. [Background technology]

[0002] Polymorphism, or polymorphism, is a unique property of some molecules and molecular compositions, where the same molecule may form different crystals due to differences in arrangement. These crystals have different crystal structures and physical properties, such as solubility, stability, hygroscopicity, X-ray diffraction spectrum, etc. Polymorphism of drug molecules has attracted increasing attention. Many pharmacoactive organic compounds can crystallize in one or more three-dimensional crystal structures. However, it is usually not possible to predict whether a particular organic pharmaceutical compound will form different crystal forms, nor is it possible to predict the structure and properties of the crystal forms themselves. The development of novel crystal forms or polymorphs of pharmacopoeially acceptable compounds can provide an opportunity to improve the overall performance of pharmaceutical derived crystals.

[0003] Regarding the compound (R)-2-(1-(2-(1-hydroxyethyl)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)piperidin-4-yl)acetonitrile, its structural formula is as shown in formula (I). [ka] At present, research on the crystalline form of this compound has not yet been conducted. The novel crystalline form of the compound of formula (I) provided by the present invention has the characteristics of good stability, high solubility, and high bioavailability, and therefore has a wide range of applicability. Summary of the Invention

[0004] The present invention aims to provide a novel crystalline form of the compound (R)-2-(1-(2-(1-hydroxyethyl)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)piperidin-4-yl)acetonitrile (hereinafter referred to as the compound of formula (I)).

[0005] The present invention provides crystalline form A of compound of formula (I), [ka] The powder X-ray diffraction spectrum of the above crystalline form A has characteristic peaks at 2θ angles of 8.6°±0.2°, 9.8°±0.2°, 10.7°±0.2°, 11.2°±0.2°, 12.3°±0.2°, 12.9°±0.2°, 16.0°±0.2° and 19.0°±0.2°.

[0006] In some embodiments, the powder X-ray diffraction spectrum of crystalline form A has characteristic peaks at 2θ angles of 8.6°±0.2°, 9.8°±0.2°, 10.7°±0.2°, 11.2°±0.2°, 12.3°±0.2°, 12.9°±0.2°, 16.0°±0.2°, 17.0°±0.2°, 17.4°±0.2°, 17.8°±0.2°, 19.0°±0.2°, 19.9°±0.2° and 21.2°±0.2°.

[0007] In some embodiments, the main data of the powder X-ray diffraction spectrum of the crystalline form A is shown in Table 1.

[0008] [Table 1-A]

[0009] [Table 1-B]

[0010] In some embodiments, the crystalline form A has an X-ray powder diffraction spectrum essentially as shown in FIG.

[0011] In some embodiments, the crystalline form A has an overlay of a differential scanning calorimetry (DSC) spectrum and a thermogravimetric analysis (TGA) spectrum essentially as shown in FIG.

[0012] In some embodiments, a stereochemical diagram of crystalline form A is shown in FIG.

[0013] In some embodiments, the crystalline form A is an anhydrous crystalline form.

[0014] The present invention further provides a process for preparing crystalline form A, the process comprising the steps of: 1) dissolving a compound of formula (I) in a crystallization solvent; 2) concentrating and filtering.

[0015] The crystallization solvent is selected from ethanol (EtOH), n-heptane, isopropanol (IPA), 2-butanol, butanone (MEK), ethyl acetate (EtOAc), 2-methyltetrahydrofuran (2-MeTHF), tetrahydrofuran (THF), methyl t-butyl ether (MTBE), and a mixture of any two of the above solvents.

[0016] In some embodiments of the invention, the crystallization solvent is selected from ethanol.

[0017] The present invention provides a method for preparing crystalline form A, which comprises dissolving compound of formula (I) in ethanol until it becomes transparent, concentrating the solution, stirring the resulting concentrate to precipitate a solid, filtering and drying to obtain said crystalline form A.

[0018] In some embodiments, the concentration is carried out at a temperature of 35°C to 55°C.

[0019] In some embodiments, the concentration of the concentrated solution is 0.5 to 2 g / mL.

[0020] In some embodiments, the stirring temperature is from 5°C to 15°C.

[0021] The present invention further provides a crystalline form H of compound of formula (I), wherein the powder X-ray diffraction spectrum of said crystalline form H is 9.4°±0.2°, 11.0°±0.2°, 14.1°±0.2°, 16.0°±0.2°, 17.8°±0.2°, 19.3°±0.2°, and 21.9°±0. It has a characteristic peak at a 2θ angle of .2°.

[0022] In some embodiments, the powder X-ray diffraction spectrum of crystalline form H has characteristic peaks at 2θ angles of 9.4°±0.2°, 11.0°±0.2°, 11.7°±0.2°, 14.1°±0.2°, 15.4°±0.2°, 16.0°±0.2°, 17.8°±0.2°, 19.3°±0.2°, 20.9°±0.2°, and 21.9°±0.2°.

[0023] In some embodiments, the crystalline form H has an X-ray powder diffraction spectrum essentially as shown in FIG.

[0024] In some embodiments, the crystalline form H has an overlay of a differential scanning calorimetry (DSC) spectrum and a thermogravimetric analysis (TGA) spectrum essentially as shown in FIG.

[0025] In some embodiments, the crystalline form H is an anhydrous crystalline form.

[0026] The present invention further provides crystalline form S of compound of formula (I), wherein the powder X-ray diffraction spectrum of said crystalline form S has characteristic peaks at 2θ angles of 9.1°±0.2°, 10.1°±0.2°, 13.4°±0.2°, 15.5°±0.2°, 16.0°±0.2°, 17.8°±0.2°, 19.7°±0.2°, and 21.8°±0.2°.

[0027] In some embodiments, the powder X-ray diffraction spectrum of crystalline form S has characteristic peaks at 2θ angles of 9.1°±0.2°, 10.1°±0.2°, 13.4°±0.2°, 15.5°±0.2°, 16.0°±0.2°, 17.8°±0.2°, 19.7°±0.2°, 21.0°±0.2°, 21.8°±0.2°, 23.3°±0.2°, 24.0°±0.2°, and 24.8°±0.2°.

[0028] In some embodiments, the crystalline form S has an X-ray powder diffraction spectrum essentially as shown in FIG.

[0029] In some embodiments, the crystalline form S has an overlay of a differential scanning calorimetry (DSC) spectrum and a thermogravimetric analysis (TGA) spectrum essentially as shown in FIG.

[0030] In some embodiments, the crystalline form S is an anhydrous crystalline form.

[0031] The present invention further provides crystalline form O of the compound of formula (I), wherein the powder X-ray diffraction spectrum of said crystalline form O has characteristic peaks at 2θ angles of 10.3°±0.2°, 11.9°±0.2°, 14.2°±0.2°, 15.3°±0.2°, 19.6°±0.2°, 20.3°±0.2°, 20.5°±0.2°, and 21.4°±0.2°.

[0032] In some embodiments, the powder X-ray diffraction spectrum of crystalline form O has characteristic peaks at 2θ angles of 10.3°±0.2°, 11.9°±0.2°, 14.2°±0.2°, 15.3°±0.2°, 19.6°±0.2°, 20.3°±0.2°, 20.5°±0.2°, 21.4°±0.2°, 25.6°±0.2°, 28.6°±0.2°, 29.4°±0.2°, and 30.0°±0.2°.

[0033] In some embodiments, the crystalline form O has an X-ray powder diffraction spectrum essentially as shown in FIG.

[0034] In some embodiments, the crystalline form O has an overlay of a differential scanning calorimetry (DSC) spectrum and a thermogravimetric analysis (TGA) spectrum essentially as shown in FIG.

[0035] In some embodiments, the crystalline form O is an anhydrous crystalline form.

[0036] The present invention further provides crystalline form P of compound of formula (I), wherein the powder X-ray diffraction spectrum of said crystalline form P has characteristic peaks at 2θ angles of 9.5°±0.2°, 16.5°±0.2°, 19.6°±0.2°, 20.3°±0.2°, 23.9°±0.2°, and 25.1°±0.2°.

[0037] In some embodiments, the powder X-ray diffraction spectrum of crystalline form P has characteristic peaks at 2θ angles of 9.5°±0.2°, 16.5°±0.2°, 19.6°±0.2°, 20.3°±0.2°, 23.9°±0.2°, 25.1°±0.2°, and 26.3°±0.2°, and 28.9°±0.2°.

[0038] In some embodiments, the crystalline form P has an X-ray powder diffraction spectrum essentially as shown in FIG.

[0039] In some embodiments, the crystalline form P has an overlay of a differential scanning calorimetry (DSC) spectrum and a thermogravimetric analysis (TGA) spectrum essentially as shown in FIG.

[0040] In some embodiments, the crystalline form P is an anhydrous crystalline form.

[0041] The present invention further provides a crystalline form Q of compound of formula (I), wherein the powder X-ray diffraction spectrum of said crystalline form Q has characteristic peaks at 2θ angles of 8.5°±0.2°, 14.5°±0.2°, 15.0°±0.2°, 16.8°±0.2°, 19.4°±0.2°, 23.6°±0.2°, 24.8°±0.2°, 26.3°±0.2°, and 27.4°±0.2°.

[0042] In some embodiments, the powder X-ray diffraction spectrum of crystalline form Q has characteristic peaks at 2θ angles of 8.5°±0.2°, 14.5°±0.2°, 15.0°±0.2°, 15.8°±0.2°, 16.8°±0.2°, 18.8°±0.2°, 19.4°±0.2°, 20.1°±0.2°, 23.6°±0.2°, 24.8°±0.2°, 26.3°±0.2°, and 27.4°±0.2°.

[0043] In some embodiments, the main data of the powder X-ray diffraction spectrum of the crystalline form Q is shown in Table 2.

[0044] [Table 2-A]

[0045] [Table 2-B]

[0046] In some embodiments, the crystalline form Q has an X-ray powder diffraction spectrum essentially as shown in FIG.

[0047] In some embodiments, the crystalline form Q has a polarized light microscope photograph essentially as shown in FIG.

[0048] In some embodiments, the crystalline form Q has an overlay of a differential scanning calorimetry (DSC) spectrum and a thermogravimetric analysis (TGA) spectrum essentially as shown in FIG.

[0049] In some embodiments, the crystalline form Q is essentially the same as shown in FIG. 1 H-nuclear magnetic resonance spectrum ( 1 H-NMR spectrum.

[0050] In some embodiments, the crystalline form Q has a dynamic gas sorption spectrum essentially as shown in FIG.

[0051] In some embodiments, the crystalline form Q is a crystalline form of a hydrate of the compound of formula (I).

[0052] The present invention further provides a method for preparing crystalline form Q, which comprises stirring crystalline form A in an aqueous ethanol solution, centrifuging and drying to obtain said crystalline form Q.

[0053] In some embodiments, the water activity value of the ethanol aqueous solution is 0.6 to 0.8.

[0054] The present invention further provides crystalline form M of compound of formula (I), wherein the powder X-ray diffraction spectrum of said crystalline form M has characteristic peaks at 2θ angles of 8.7°±0.2°, 9.9°±0.2°, 17.4°±0.2°, 18.6°±0.2°, 18.9°±0.2°, 20.6°±0.2°, and 26.5°±0.2°.

[0055] In some embodiments, the powder X-ray diffraction spectrum of crystalline form M has characteristic peaks at 2θ angles of 8.7°±0.2°, 9.9°±0.2°, 13.1°±0.2°, 17.4°±0.2°, 18.6°±0.2°, 18.9°±0.2°, 20.6°±0.2°, 26.5°±0.2°, 28.1°±0.2°, and 31.1°±0.2°.

[0056] In some embodiments, the crystalline form M has an X-ray powder diffraction spectrum essentially as shown in FIG.

[0057] In some embodiments, the crystalline form M has an overlay of a differential scanning calorimetry (DSC) spectrum and a thermogravimetric analysis (TGA) spectrum essentially as shown in FIG.

[0058] In some embodiments, the crystalline form M is essentially the same as shown in FIG. 1 H-nuclear magnetic resonance spectrum ( 1 H-NMR spectrum.

[0059] In some embodiments, the crystalline form M is a hydrate crystalline form of the compound of formula (I).

[0060] The present invention further provides a crystalline form composition of the above crystalline form. In some embodiments of the present invention, the above crystalline form A accounts for 50% or more, preferably 80% or more, more preferably 90% or more, and most preferably 95% or more by weight of the crystalline form composition.

[0061] The present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of crystalline form A, crystalline form Q, or a mixture thereof, and a pharma- ceutically acceptable carrier, diluent or excipient.

[0062] The present invention further provides a veterinary pharmaceutical composition comprising a therapeutically effective amount of crystalline Form A, crystalline Form Q, or a mixture thereof, and a pharma- ceutically acceptable carrier, diluent or excipient.

[0063] The present invention further provides the use of crystalline form A, crystalline form Q, or a mixture thereof in the preparation of a medicament.

[0064] In some embodiments, the medicament is for treating, preventing and / or delaying an allergic reaction, allergic dermatitis, atopic dermatitis, eczema, pruritus or psoriasis.

[0065] In some embodiments, the medicament is for treating, preventing and / or delaying an allergic reaction, allergic dermatitis, atopic dermatitis, eczema, pruritus or psoriasis in a mammal.

[0066] In some embodiments, the mammal comprises a companion animal.

[0067] In some embodiments, the mammal comprises a domestic animal.

[0068] In some embodiments, the medicament is for treating a disease mediated by JAK kinase (JAK1).

[0069] The present invention further provides a method for treating and / or preventing a disease, comprising administering a therapeutically effective amount of crystalline form A, crystalline form Q or a mixture thereof to a mammalian subject.

[0070] In some embodiments, the therapeutically effective amount is between 0.01 mg / kg body weight / day and 100 mg / kg body weight / day.

[0071] In some embodiments, the therapeutically effective amount is between 0.1 mg / kg body weight / day and 30 mg / kg body weight / day.

[0072] In some embodiments, the disease is mediated by JAK kinase (JAK1).

[0073] In some embodiments, the mammal comprises a companion animal.

[0074] In some embodiments, the mammal comprises a domestic animal.

[0075] In some embodiments, crystalline form A, crystalline form Q or a mixture thereof is administered orally, parenterally or topically.

[0076] The novel crystalline form of the compound (R)-2-(1-(2-(1-hydroxyethyl)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)piperidin-4-yl)acetonitrile provided by the present invention has the characteristics of good stability, high solubility, and high bioavailability, and therefore has a wide range of applicability. Of course, it is not necessary to simultaneously achieve all of the above advantages when carrying out any product or method of the present invention.

[0077] Related Definitions and Explanations In the present invention, the term "essentially" used in "having a powder X-ray diffraction spectrum essentially as shown in FIG. 1" or "whose powder X-ray diffraction spectrum is essentially as shown in FIG. 1" means that the exact positions of the peaks in the drawing should not be interpreted as absolute values. As will be understood by those skilled in the art, the 2θ values ​​of the powder X-ray diffraction spectrum may have errors due to different measurement conditions (e.g., equipment and instruments used) and different samples. The measurement error of the diffraction angle of the powder X-ray diffraction spectrum is 5% or less, and is usually within a certain range from a given value. An error of ±0.2° is considered appropriate. It should also be understood that the relative intensities of the peaks may vary depending on the test conditions and sample preparation methods, such as the preferred orientation of grains in the sample. The use of automatic or fixed divergence slits also affects the calculation of relative intensities. The intensities shown in the XRD curves contained herein are illustrative only and cannot be used for absolute comparisons.

[0078] The water activity value described in the present invention refers to the value obtained by dividing the equilibrium vapor pressure of water in an aqueous ethanol solution by the saturated vapor pressure of pure water at the same temperature.

[0079] The present invention does not limit the drying temperature as long as the object of the present invention can be achieved. For example, drying may be performed at a temperature in the range of 10°C to 30°C.

[0080] The therapeutically effective amount according to the present invention refers to the amount of drug sufficient to affect the treatment of the disease, illness or condition when used to treat the disease or at least one clinical symptom of the disease or illness. The "therapeutically effective amount" may vary depending on the drug, the symptoms of the disease or illness, or the severity of the symptoms of the disease or illness, etc. In any case, the appropriate dose may be obvious to a person skilled in the art or may be determined by routine testing.

[0081] The pharmaceutically acceptable carrier, diluent or excipient according to the present invention refers to a non-toxic carrier, diluent or excipient that does not adversely affect the pharmacological activity of the crystalline form to be incorporated and is safe for use in animals.The pharmaceutically acceptable carrier, diluent or excipient that can be used in the crystalline form of the present invention includes, but is not limited to, ion exchange agents, alumina, aluminum stearate, magnesium stearate, lecithin, serum protein, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, vegetable saturated fatty acid partial glyceride mixtures, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, silica gel, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances (e.g., microcrystalline cellulose, hydroxypropylmethylcellulose, lactose monohydrate, sodium lauryl sulfate and cross-linked sodium carboxymethylcellulose), polyethylene glycol, sodium carboxymethylcellulose, polyacrylate, wax, polyethylene-polyoxypropylene block polymer, polyethylene glycol and wool fat.

[0082] The pharmaceutical composition comprising the crystalline form of the present invention can be administered orally, nasally, rectally, parenterally or topically. For oral administration, the pharmaceutical composition can be formulated into a conventional solid preparation such as a tablet, powder, granule, capsule, or liquid preparation such as a water suspension or an oil-water suspension, or other liquid preparation such as a syrup, solution, suspension, etc. For parenteral administration, the pharmaceutical composition can be formulated into a solution, aqueous solution, oil suspension, lyophilized powder, etc.

[0083] In order to more clearly explain the embodiments of the present invention and the technical solutions of the prior art, the following briefly introduces the drawings that need to be used in the embodiments and the prior art. Obviously, the following drawings are only some embodiments of the present invention, and those skilled in the art can obtain other embodiments based on these drawings. [Brief description of the drawings]

[0084] [Figure 1] FIG. 1 is a powder X-ray diffraction spectrum of the amorphous compound. [Diagram 2] FIG. 2 is the powder X-ray diffraction spectrum of crystalline form A. [Diagram 3] FIG. 3 is an overlay of the differential scanning calorimetry spectrum and the thermogravimetric analysis spectrum of crystalline form A. [Figure 4] FIG. 4 is a diagram of the three-dimensional structure of crystalline form A. [Diagram 5] FIG. 5 is the powder X-ray diffraction spectrum of crystalline form H. [Figure 6] FIG. 6 is an overlay of the differential scanning calorimetry spectrum and the thermogravimetric analysis spectrum of crystalline form H. [Figure 7] FIG. 7 is the powder X-ray diffraction spectrum of crystalline form S. [Figure 8] FIG. 8 is an overlay of the differential scanning calorimetry spectrum and the thermogravimetric analysis spectrum of crystalline form S. [Figure 9] FIG. 9 is the powder X-ray diffraction spectrum of crystalline form O. [Figure 10] FIG. 10 is an overlay of the differential scanning calorimetry spectrum and the thermogravimetric analysis spectrum of crystalline form O. [Figure 11] FIG. 11 is the powder X-ray diffraction spectrum of crystalline form P. [Figure 12] FIG. 12 is an overlay of the differential scanning calorimetry spectrum and the thermogravimetric analysis spectrum of crystalline form P. [Figure 13] FIG. 13 is a powder X-ray diffraction spectrum of crystalline form Q. [Figure 14] FIG. 14 is a polarizing microscope photograph of crystalline form Q. [Figure 15] FIG. 15 is an overlay of the differential scanning calorimetry spectrum and the thermogravimetric analysis spectrum of crystalline form Q. [Figure 16] FIG. 16 is the 1H-nuclear magnetic resonance spectrum of crystalline form Q. [Figure 17] FIG. 17 is a dynamic gas sorption spectrum of crystalline form Q. [Figure 18] FIG. 18 is the powder X-ray diffraction spectrum of crystalline form M. [Figure 19] FIG. 19 is an overlay of the differential scanning calorimetry spectrum and the thermogravimetric analysis spectrum of crystalline form M. [Figure 20] FIG. 20 is the 1H-nuclear magnetic resonance spectrum of crystalline form M. [Figure 21] FIG. 21 is a graph showing changes in skin thickness in each group during treatment of an atopic dermatitis animal model with crystalline form A. [Figure 22] FIG. 22 is a graph showing changes in the average ear thickness of each group during treatment of an animal model of atopic dermatitis with crystalline form A. [Diagram 23] FIG. 23 is a graph showing changes in the skin damage severity score in each group during treatment of an atopic dermatitis animal model with crystalline form A. [Figure 24] FIG. 24 is a graph showing changes in skin thickness in each group during treatment of an animal model of psoriasis with crystalline form A. [Diagram 25] FIG. 25 is a graph showing changes in PASI scores in each group during treatment of an animal model of psoriasis with crystalline form A. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0085] Abbreviation: XRPD: X-ray powder diffraction; TGA: thermogravimetric analysis, DSC: differential scanning calorimeter; 1 H-NMR: 1 H-nuclear magnetic resonance spectrum, PLM: Polarized Light Microscope; DVS: Dynamic Vapour Sorption Meter; SXRD: Single crystal X-ray diffraction; HPLC: High Performance Liquid Chromatography; LC-MS / MS: Liquid Chromatography Mass Spectroscopy; ACN: acetonitrile; DCM: dichloromethane, n-heptane: n-heptane, MeOH: methanol, EtOH: ethanol, EtOAc: ethyl acetate, IPA: Isopropanol, 2-MeTHF: 2-methyltetrahydrofuran, 2-Butanol: 2-butanol, MEK: butanone, THF: tetrahydrofuran; MTBE: methyl t-butyl ether; FaSSIF: fasting artificial intestinal fluid, SIF: artificial intestinal fluid, FeSSIF: fed state artificial intestinal fluid; SGF: artificial gastric fluid, RH: relative humidity, AD: atopic dermatitis; SI: Skin injury severity index; PASI: Psoriasis Area and Severity Index; Mean±SD: Mean ± Standard Deviation Mean±SEM: Mean ± standard error AAALAC: Association for Assessment and Accreditation of Laboratory Animal Care International; SPF: specific pathogen free animals; IVC: individually ventilated cage.

[0086] In order to make the objectives, technical solutions and advantages of the present application clearer, the present invention will be described in more detail below by way of examples with reference to the drawings. It is clear that the described embodiments are only a part of the embodiments of the present invention, and are not all of the embodiments. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention are within the protection scope of the present invention.

[0087] Unless otherwise specified, the information on the detection equipment and the detection method used in the present invention are as follows. (1) Powder X-ray diffraction analysis

[0088] Powder X-ray diffraction data of the samples were collected under ambient conditions using a Bruker D2 powder X-ray diffractometer. The power of the X-ray emitter was 300 W. The sample stage was free of background signal, the step speed was 0.15 s / step, the total number of steps was 1837 steps, the step width was 2θ = 0.02°, the voltage was 30 kV, and the current was 10 mA. The X-ray tube used a Cu target (Kα) with a Kα2 / Kα1 intensity ratio of 0.50 (1.54439 Å / 1.5406 Å).

[0089] (2) Thermogravimetric analysis Thermogravimetric data of the samples was collected using a TA Discovery series thermogravimeter TGA550. A few milligrams of sample was placed in a Tzero aluminum pan and heated from room temperature to 300.0°C under N2 protection. The N2 flow rate was 25 mL / min and the heating rate was 10°C / min.

[0090] (3) Differential scanning calorimetry Calorimetric data of the samples was collected using a TA Discovery series differential scanning calorimeter DSC2500. A few milligrams of sample was weighed into a Tzero aluminum pan and sealed with a Tzero seal cap. It was heated to 300.0°C under N2 protection with a N2 flow rate of 50 mL / min and a heating rate of 10°C / min.

[0091] (4) Polarizing microscope The crystal morphology was observed and PLM photographs were taken under room temperature conditions using an Olympus BX3M-KMA-S polarizing microscope.

[0092] (5) Dynamic gas adsorption meter The hygroscopicity data of the samples was collected under N2 protection using an ADVENTURE series dynamic gas sorption meter. The sample weight was approximately 30 mg.

[0093] The present invention will now be described in detail with reference to specific examples. EXAMPLES

[0094] Example 1: Preparation of an amorphous form of the compound of formula (I) [ka] Step 1: Triethyloxonium tetrafluoroborate (251 mg, 1.32 mmol) and R-lactamide (118 mg, 1.32 mmol) were dissolved in 8 mL of tetrahydrofuran and reacted at room temperature for 2 hours with stirring. Concentration under reduced pressure gave a colorless oil, which was dissolved in 5 mL of absolute ethanol and added to 5 mL of absolute ethanol in which compound 2-(1-((5-amino-1-p-toluenesulfonyl-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-4-yl)acetonitrile (189 mg, 0.44 mmol) was dissolved. The temperature was raised to 75° C. and the reaction was stirred for 1 hour. After the reaction was completed, it was quenched with aqueous sodium bicarbonate solution, 30 mL of water was added, and the mixture was extracted with ethyl acetate (3×30 mL). The organic phases were combined, washed with 50 mL of saturated saline, and dried over anhydrous sodium sulfate. Then, suction filtration was performed, and the obtained filtrate was concentrated under reduced pressure, and the compound (R)-2-(1-(2-(1-hydroxyethyl)-6-p-toluenesulfonylimidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)piperidin-4-yl)acetonitrile (110 mg, yield 52%) was obtained by silica gel column chromatography. LCMS ESI(+)m / z: 479.1 (M+1).

[0095] Step 2: Compound (R)-2-(1-(2-(1-hydroxylethyl)-6-p-toluenesulfonylimidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)piperidin-4-yl)acetonitrile (110 mg, 0.23 mmol) was dissolved in 9 mL of methanol, 3 mL of 1N aqueous sodium hydroxide solution was added, and the mixture was stirred at room temperature for 16 hours to react. After the reaction was completed, the pH was adjusted to 7-8 with acetic acid, concentrated under reduced pressure, and the compound (R)-2-(1-(2-(1-hydroxylethyl)-imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)piperidin-4-yl)acetonitrile (30 mg, yield 40%) was prepared by silica gel column chromatography and preparative high performance liquid chromatography. 1 H NMR (400MHz, DMSO-d6) δ11.92(s, 1H), 8.55(s, 1H), 7.50(d, J=3.4Hz, 1H), 6.73(d, J=3.4Hz, 1H), 5.31(s, 1H), 5.16(q, J=6.6Hz, 1H), 3.65-3.5 3(m, 2H), 3.15(dd, J=30.2, 10.0Hz, 2H), 2.64(d, J6.4Hz, 2H), 2.17-2.04(m, 1H), 1.98-1.89(m, 2H), 1.72-1.60(m, 2H), 1.56(d, J=6.6Hz, 3H). LCMS ESI(+)m / z:325.0 (M+1). The XRPD spectrum after measurement is shown in Figure 1, and the obtained final product was amorphous.

[0096] (This preparation method is described on page 11 of the specification of the applicant's compound patent WO2021051899A1.)

[0097] Example 2: Preparation of crystalline form A of compound of formula (I) 15 mg of amorphous compound of formula (I) was weighed into a 4 mL glass bottle, and ethanol was added until the sample became clear. The sample was then placed into a 20 mL glass bottle containing 4 mL of n-heptane. The 20 mL glass bottle was tightly capped and left at room temperature until a solid precipitated, and the solid was separated. The solid was identified as crystalline form A by XRPD, TGA, and DSC.

[0098] Example 3: Preparation of crystalline form A of compound of formula (I) 1.5 kg of the amorphous form of compound of formula (I) was dissolved in 15 L of ethanol and stirred at 75°C to 85°C until the sample was dissolved and transparent. The mixture was then concentrated to 1.5 L to 3 L at 35°C to 55°C, and the resulting concentrate was stirred at 5°C to 15°C for 1 to 2 hours to precipitate a solid. The mixture was filtered and dried to obtain 0.95 kg of a solid. When measured by XRPD, TGA, and DSC, the resulting solid was crystalline form A.

[0099] Example 4: Preparation of crystalline form H of compound of formula (I) A 15 mg sample of crystalline form A was weighed, 0.4 mL of ACN was added, and the suspension was stirred magnetically at room temperature to obtain a suspension. After about one week, the solid was isolated and analyzed by XRPD, TGA, and DSC, which showed that the solid was crystalline form H.

[0100] Example 5: Preparation of crystalline form S of compound of formula (I) Form Q (Example 8) was heated to 165° C. to obtain a solid, which was identified as form S by XRPD, TGA, and DSC.

[0101] Example 6: Preparation of crystalline form O of compound of formula (I) A 15 mg sample of crystalline form A was weighed and added to 0.4 mL of DCM / n-heptane solution (2:1, v / v) and magnetically stirred at room temperature to obtain a suspension. After about one week, the solid was isolated and heated to 165°C under N2 protection and then cooled to room temperature. The solid was identified as crystalline form O by XRPD, TGA, and DSC.

[0102] Example 7: Preparation of crystalline form P of compound of formula (I) A 15 mg sample of crystalline form A was weighed, MeOH solvent was added, and the mixture was stirred at room temperature to obtain a transparent stock solution. The stock solution was dispensed into a 20 mL glass bottle, and under magnetic stirring conditions, 0.2 mL to 0.5 mL of corresponding water was gradually added to the glass bottle until a solid appeared, and the solid was separated. The solid was obtained after heating the solid to 120 °C, and the solid was measured by XRPD, TGA, and DSC, and was found to be crystalline form P.

[0103] Example 8: Preparation of crystalline form Q of compound of formula (I) Form A was stirred in an aqueous ethanol solution with a water activity of 0.6-0.8 until a solid was formed, centrifuged, and the collected solid was dried and analyzed by XRPD, TGA, and DSC. The resulting solid was Form Q.

[0104] Example 9: Preparation of crystalline form M of compound of formula (I) A 15 mg sample of crystalline form A was weighed, EtOH solvent was added, and the mixture was stirred at room temperature to obtain a transparent stock solution. The stock solution was dispensed into a 20 mL glass bottle and stirred under magnetic stirring conditions until a solid appeared. The corresponding EtOAc solution was gradually added in 0.2-0.5 mL portions to the glass bottle, and the mixture was gradually evaporated at room temperature to obtain a solid. The solid was determined to be crystalline form M by XRPD, TGA, and DSC.

[0105] Example 10: Single crystal X-ray diffraction (SXRD) experiments Preparation of crystals: A 15 mg sample of crystalline form A of compound of formula (I) was weighed and placed in a 15 mL test tube, and dissolved in 1 mL of dichloromethane, followed by the addition of 2 mL of ethanol. The mouth of the test tube was covered with a sealing film, 5-10 small holes were made in the sealing film with a needle, and the tube was allowed to stand to evaporate. After about 3 weeks, the solution had completely evaporated, and colorless lumpy crystals were obtained at the bottom of the test tube.

[0106] Single crystal X-ray diffraction analysis of the crystals showed that they were colorless chunks, and the size of the crystals used in the diffraction analysis was 0.09 × 0.09 × 0.08 mm. 3 It belongs to the monoclinic crystal system, the space group is P1211, and the unit cell parameters are a = 9.6796(4) Å and α = 90 o , b=14.0338(6)Å, β=108.829.218(2) o , c=14.5745(6)Å, γ=90 o and the unit cell volume V = 1873.87(14) Å 3 The number of molecules in the unit cell is Z=4, which indicates that one molecule is contained in an independent region of the unit cell.

[0107] Example 11: Thermodynamic Analysis Experiments Form H and Form S were each heated to an appropriate temperature under the protection of N2, cooled to room temperature, and then the XRPD of the solid was measured.

[0108] Results: 1) When form H was heated to 162°C, a portion of the form H sample was converted to form A, and when heated to 210°C, the sample was completely converted to form A. 2) When form S was heated to 215°C, the form S sample was converted to form A.

[0109] Analysis: 1) Referring to the TGA / DSC spectrum of crystalline form H, the weight loss of the sample heated to 210℃ was 0.6%, and the DSC showed two exothermic peaks before melting. According to the Burger-Ramberger Rule, crystalline form H and crystalline form A were in a monotropic relationship.

[0110] 2) The TGA / DSC spectrum of crystalline form S showed that the weight loss of the sample heated to 210℃ was 1.6%, and the DSC showed one exothermic peak before melting. According to the Burger-Ramberger rule, crystalline form S and crystalline form A were monotropic.

[0111] This experiment demonstrated that form A is thermodynamically more stable than forms H and S.

[0112] Example 12: Suspension competition experiments Suspension competition experiments were carried out for Form A, Form O, or Form P in IPA and 2-MeTHF solvents at room temperature and at 60°C.

[0113] The specific procedure was as follows. Excess crystalline form A was weighed out into four HPLC vials in four portions, 0.5 mL of IPA was added to two portions, and 0.5 mL of 2-MeTHF was added to the remaining two portions, and each was left for about 1 hour with magnetic stirring at room temperature and 60°C. Then, the solution was filtered through a preheated nylon film (pore size 22 μm) to obtain a saturated solution. 1 mg to 2 mg each of crystalline form A, crystalline form O, and crystalline form P were added to the saturated filtrate, and the mixture was stirred magnetically at room temperature or 60°C for about 1 day, centrifuged, and the obtained solid matter was measured by XRPD measurement. The suspensions were The results of the turbidity competition experiment are shown in Table 3.

[0114] [Table 3]

[0115] The results showed that at room temperature and 60°C, the solids obtained in both solvents were all crystalline form A. This indicated that compared with crystalline forms O and P, crystalline form A was more stable at room temperature and 60°C.

[0116] Example 13: Dynamic Solubility The dynamic solubilities of crystalline forms A and Q in three biological solvents (artificial gastric fluid, fasting artificial intestinal fluid, and fed artificial intestinal fluid) were measured at 37°C to evaluate the solubility and stability of the two crystalline forms.

[0117] The specific procedure for preparing the biological solvent was as follows:

[0118] (1) Preparation of FaSSIF: a. 42 mg of NaOH, 395 mg of NaH2PO4·H2O, and 619 mg of NaCl were weighed out into a 100 mL beaker, and 90 mL of deionized water was added to dissolve them. b. The pH was adjusted to 6.5 with 1N NaOH or 1N HCl, and the volume was adjusted to 100 mL with deionized water to obtain FaSSIF blank solvent. c. 224 mg of simulated intestinal fluid (hereinafter referred to as SIF powder) was weighed out, and 50 mL of the above FaSSIF blank solvent was added and stirred until completely dissolved. Then, the volume was adjusted to 100 mL with FaSSIF blank solvent to prepare FaSSIF, which is a solvent. d. The mixture was left to stand at room temperature for 2 hours before use.

[0119] (2) Preparation method of FeSSIF: a. 404 mg of NaOH, 865 mg of glacial acetic acid, and 1189 mg of NaCl were weighed out into a 100 mL beaker, and 90 mL of deionized water was added to dissolve them. b. The pH was adjusted to 5.0 with 1N NaOH or 1N HCl, and the solution was diluted to 100 mL with deionized water to obtain FeSSIF blank solvent. c. 1120 mg of SIF powder was weighed out, and 50 mL of the above FeSSIF blank solvent was added and stirred until dissolved. Then, the solution was diluted to 100 mL with FeSSIF blank solvent to prepare the solvent FeSSIF. d. The solution was left to stand at room temperature before use to obtain a clear solution.

[0120] (3) Preparation method of SGF: a. 200 mg of NaCl was weighed out into a 100 mL beaker, and 90 mL of deionized water was added to dissolve it. b. The pH was adjusted to 1.6 with 1N HCl, and the volume was adjusted to 100 mL with deionized water to obtain SGF blank solvent. c. 6 mg of SIF powder was weighed out, and 50 mL of the above SGF blank solvent was added and stirred until dissolved. Then, the volume was adjusted to 100 mL with SGF blank solvent to prepare SGF, which is a solvent. d. Before use, the solution was left to stand at room temperature to obtain a clear solution.

[0121] The specific method for measuring the dynamic solubility was as follows: Approximately 40 mg of crystalline form A or crystalline form Q was added to 4 mL of each of the three biological solvents, and the solution was shaken (100 rpm) at a constant temperature of 37°C. After 1, 4, and 24 hours, 1.3 mL of the suspension (or clear solution) was taken. The suspension was centrifuged for 5 min. The resulting solid was subjected to crystal form detection (XRPD) and the supernatant / clear liquid was subjected to solubility and pH measurements after filtration.

[0122] Solubility data for the samples was collected using a high performance liquid chromatograph equipped with an image diode array detector.

[0123] Measurement results: The measurement results of dynamic solubility are shown in Table 4.

[0124] [Table 4]

[0125] Remarks: Starting samples: Form A, Form Q.

[0126] --: The crystal form of the sample that had not been dissolved for 24 hours was similar to that of the starting sample, so the crystal form of the samples that had not been dissolved for 1 or 4 hours was not measured.

[0127] As can be seen from the results, within 24 hours at 37°C, 1) the solubility of crystalline form A in all three solvents (SGF / FaSSIF / FeSSIF) was greater than that of crystalline form Q. 2) When crystalline forms A and Q were suspended and stirred in SGF / FaSSIF / FeSSIF for 24 hours, all crystalline forms were stable.

[0128] Example 14: Solid State Stability Measurement method: 17-20 mg samples of crystalline form A and crystalline form Q were weighed into HPLC vials and left in an open state under three conditions: 1) 25°C / 60%RH, 2) 40°C / 75%RH, and 3) 60°C. Purity measurements (via HPLC) and crystalline form detection (via XRPD) were performed on the starting sample, the sample stored for one week, and the sample stored for two weeks. Specific results are shown in Table 5.

[0129] [Table 5]

[0130] The results show that: 1) Purity: After 1 and 2 weeks of storage under the selected conditions, there was no obvious change in the purity of crystal form A and crystal form Q. 2) Change in crystal form: The comparison of XRPD results of crystal forms A and Q stored under three different conditions for 0, 1, and 2 weeks showed that after 1 and 2 weeks of storage under the selected conditions, there was no change in the crystal form of either crystal form A or crystal form Q.

[0131] Conclusion: Both Form A and Form Q have good solid-state stability.

[0132] Example 15: Stability study of crystalline forms Form M was stored at 25° C. and 55% RH for 35 days, and the solid was analyzed by XRPD. Form M was converted to Form A.

[0133] The results showed that under ambient temperature and humidity, crystalline form M was unstable and easily converted to the stable crystalline form A.

[0134] Example 16: Hygroscopicity Experiment The hygroscopicity of the above crystalline forms was measured according to the Guiding Principles for Drug Hygroscopicity Testing, Part 4 General Principles 9103, of the 2020 edition of the Chinese Pharmacopoeia.

[0135] The evaluation criteria for moisture absorption were as follows: Deliquescent: Absorbs enough water to become liquid. Highly hygroscopic: Weight increase due to moisture absorption is 15% or more. Hygroscopic: Weight increase due to moisture absorption is less than 15% and more than 2%. Low moisture absorption: Weight increase due to moisture absorption is less than 2%, and more than 0.2%. Non-hygroscopic or substantially non-hygroscopic: The weight gain due to moisture absorption is less than 0.2%.

[0136] As can be seen from the measurement results, the weight increase due to moisture absorption of crystalline form A was 0.05%, which means that it was non-hygroscopic or substantially non-hygroscopic. Compared with other crystalline forms described in the present application, crystalline form A was more suitable for the preparation of solid dosage forms. Example 17: Influence factor testing

[0137] The stability of the crystal forms of the present invention under accelerated test conditions was evaluated. Crystal form A, crystal form H, crystal form S, crystal form O, crystal form P, crystal form Q and crystal form M were subjected to stability tests in an environment of 5000 Lx light irradiation, a high temperature environment of 60°C and a high humidity environment of 90% RH ± 5% RH. Samples were taken on the 0th, 5th, 10th and 30th days, respectively. The content, total impurities and XRPD spectrum of the sample were recorded and compared with the initial data. The comparison results showed that crystalline form A, crystalline form H, crystalline form S, crystalline form O, crystalline form P, crystalline form Q and crystalline form M have good stability, and in particular, crystalline form A has better stability. The data of the influence factor test of crystalline form A are shown in Table 5a below.

[0138] [Table 5a]

[0139] Example 18: Pharmacokinetic study Twelve SD rats were divided into two groups (6 rats / group), half female and half male, and each group was given a single oral gavage. Blood was then collected from the retinal venous plexus at the designated time points, and plasma was separated and stored in a -80℃ refrigerator.

[0140] After the plasma samples were subjected to protein precipitation with acetonitrile, the supernatant was removed and diluted with water, and 5 μL was taken and subjected to LC-MS / MS detection.

[0141] The results showed that the sample of crystalline form A had high in vivo bioavailability, which met the requirements for pharmaceutical development.

[0142] Pharmacology Testing Example A Pharmacological Effects in Animal Models of Atopic Dermatitis 1. Experimental materials (1) Laboratory animals and breeding methods 55 BALB / C mice, female, 6 weeks old at the time of purchase, 8 weeks old at the time of the experiment, weighing 18g-20g. The animals were purchased from Shanghai Lingcheng Biological Science and Technology Co., Ltd. (SCXK (Shanghai) 2018-0003), with the Experimental Animal Production Qualification Certificate Number of 20180003012342, and the Experimental Animal Use Permit Number of SYXK (Shanghai) 2020-0001 (Weiya Biotechnology (Shanghai) Co., Ltd.).

[0143] All mice were housed in an SPF-grade IVC constant temperature and pressure system animal breeding room, with a temperature of 20°C to 26°C, humidity of 40% to 70%, and a light cycle of 12 hours light and 12 hours dark. Six mice were housed in each cage, the cage size was 325mm × 210mm × 180mm, and the bedding in the cage was changed twice a week. Throughout the entire course of the experiment, all experimental mice had free access to food and drink, and all feed and water were autoclaved and changed twice a week.

[0144] (2) Test sample a. Tofacitinib, free base, purity 98%, total amount 200 mg, storage temperature 4°C b. Upadacitinib, free base, purity 98%, total amount 70 mg, storage temperature 4°C c. Crystalline form A, free base, purity 99.7%, total amount 300mg, storage temperature 4℃

[0145] 2. Experimental steps and methods Modeling and administration method: A hair removal cream was used to remove hair from the top of the head to the back of each animal in an area of ​​approximately 5 cm x 2 cm. The application time of the hair removal cream was controlled within 2 minutes. After that, the hair removal site was washed with warm water, and the animal's hair was dried with a hair dryer immediately after washing the hair removal agent, and the animal was placed on a 37°C constant temperature electric blanket for 1 to 2 hours. After the animal was allowed to freely behave normally, it was normally housed in a breeding cage for 1 day to recover (if the animal's skin was red, swollen, and damaged after hair removal, the animal was removed). The next day, 42 animals with normal skin were selected and randomly divided into groups according to weight, with 6 animals in each group, for a total of 7 groups. Except for the G1 blank control group, each animal in the other groups was induced by uniformly applying 200 μL of 0.5 wt% dinitrochlorobenzene solution (the solvent was a mixture of acetone and olive oil in a mass ratio of 3:1) to the back and ears every day for 3 consecutive days (the first stage of induction). The second stage of induction was started after 14 days, and the administration treatment was started simultaneously with induction using 1 wt% dinitrochlorobenzene solution (the solvent was a mixture of acetone and olive oil in a mass ratio of 3:1) every 3 days until the end of the experiment. The grouping and administration conditions are shown in Table 6.

[0146] [Table 6]

[0147] The preparation method of the test drugs is shown in Table 7.

[0148] [Table 7]

[0149] 3. Experimental observation Throughout the course of the study, all use and observation of laboratory animals was conducted in accordance with the relevant standards for the use and care of AAALAC animals.

[0150] 4. Evaluation indicators Skin thickness (2 layers): The thickness of the 2 layers of skin on the back was measured using a caliper on the 1st day before modeling, and on the 14th, 17th, 20th, 23rd, 26th, and 28th days after modeling.

[0151] Auricular thickness: The thickness of the right auricle was measured using a caliper on the 1st day before modeling, and on the 14th, 17th, 20th, 23rd, 26th, and 28th days after modeling.

[0152] AD-SI score: The symptom score was based on the clinical SI score standard. Three indicators, skin color / erythema, erythema with scale, scale / skinning / lichenification, thickening, and thickening / edema, were scored for a total of 12 points. The score standard was as follows:

[0153] Erythema / skin color: Score 0: no erythema, score 1: mild and light pink, score 2: moderate and red, score 3: significant and deep red, score 4: very significant and very deep red.

[0154] Scaling / molting / lichenification: Score 0: no scale / molting / lichenification. Score 1: mild and some parts of the epidermis have scale / molting / lichenification, but it is mainly slight. Score 2: moderate and most of the skin surface is completely or incompletely covered with sheet-like scale / molting / lichenification. Score 3: noticeable and almost the entire skin is covered with scale / molting / lichenification, and the scale / molting / lichenification is relatively thick and layered. Score 4: very noticeable and the entire skin is covered with scale / molting / lichenification, and the scale / molting / lichenification is thick and layered.

[0155] Thickening / edema: Score 0: No thickening / edema, same as normal skin; Score 1: Mild and slightly higher than normal skin surface; Score 2: Moderate and moderately elevated, plaque edges are rounded or sloping; Score 3: Significant and plaque thickening, swelling evident; Score 4: Very significant and very thickening, swelling evident; Score 5: Very significant and very thickening, swelling evident; Score 6: Very significant and very thickening, swelling evident; Score 7: Very significant and very thickening, swelling evident; Score 8: Very significant and very thickening, swelling evident; Score 9: Very significant and very thickening, swelling evident; Score 10: Very significant and very thickening, swelling evident; Score 11: Very significant and very thickening, swelling evident; Score 12: Very significant and very thickening, swelling evident; Score 13: Very significant and very thickening, swelling evident; Score 14: Very significant and very thickening, swelling evident; Score 15: Very significant and very thickening, swelling evident; Score 16: Very significant and very thickening, swelling evident; Score 17: Very significant and very thickening, swelling evident; Score 18: Very significant and very thickening, swelling evident; Score 19: Very significant and very thickening, swelling evident; Score 20: Very significant and very thickening, swelling evident; Score 21: Very significant and very thickening, swelling evident; Score 22: Very significant and very thickening, swelling evident; Score 23: Very significant and very thickening, swelling evident; Score 24: Very significant and very thickening, swelling evident; Score 25: Very significant and very thickening, swelling evident; Score 26: Very significant and very thickening, swelling evident; Score 27: Very significant and very thickening, swelling evident; Score 28: Very significant and very thickening, swelling evident; Score 29: Very significant and very thickening, swelling evident; Score 30: Very significant and very thickening, swelling evident; Score 31: Very significant and very is very clear. Inhibition rate of skin / ear thickening (%)=1-[(thickness of skin / ear in treatment group-thickness of skin / ear in blank control group) / (thickness of skin / ear in negative control group-thickness of skin / ear in blank control group)]%.

[0156] 5. End of experiment The experiment was terminated after 14 days of treatment, and the animals were euthanized. The back skin and ears of the mice were dissected and separated, one half of which was fixed and preserved in formalin, and the other half was stored at -80°C.

[0157] 6. Data analysis All data were expressed as Mean ± SD or Mean ± SEM. Data were subjected to normal distribution test and test of homogeneity of variance using statistical analysis software SPSS23.0. Depending on the results, the test of homogeneity of variance was selected, and depending on the results, one-way analysis of variance was selected. * P<0.05 was considered to indicate a statistically significant difference.

[0158] 7. Experimental results (1) Effect of the test drug on skin thickness The changes in average skin thickness and the inhibitory effect of each group on the 10th day of treatment are shown in Tables 8, 9 and FIG. 21. FIG. 21 shows the changes in skin thickness of each group during the treatment period (Note: * P < 0.05, ** P < 0.01, *** P<0.001 in all cases compared with the G2 negative control group.

[0159] [Table 8]

[0160] remarks: * P < 0.05, ** P < 0.01, *** P<0.001 compared with the G2 negative control group.

[0161] [Table 9]

[0162] remarks: * P < 0.05, ** P < 0.01, *** P<0.001 compared with the G2 negative control group.

[0163] (2) Effect of the test drug on ear thickness The changes in the average ear thickness and the inhibitory effect of each group on the 10th day of treatment are shown in Tables 10 and 11 and FIG. 22. FIG. 22 shows the changes in the average ear thickness of each group during the treatment period (Note: * P < 0.05, ** P < 0.01, *** P<0.001 in all cases compared with the G2 negative control group.

[0164] [Table 10]

[0165] remarks: * P < 0.05, ** P < 0.01, *** P<0.001 compared with the G2 negative control group.

[0166] [Table 11]

[0167] remarks: * P < 0.05, ** P < 0.01, *** P<0.001 compared with the G2 negative control group.

[0168] (3) Effect of the test drug on the AD-SI score in AD model animals The changes in AD-SI score for each group (n=6) up to 10 days after treatment are shown in Table 12 and Figure 23. Figure 23 shows the changes in AD-SI score for each group during the treatment period.

[0169] [Table 12]

[0170] remarks: * P < 0.05, ** P < 0.01, *** P<0.001 compared with the G2 negative control group.

[0171] Results analysis: On the 10th day of treatment, the mean back bilayer skin thickness of the G7 group treated with crystalline form A (30 mg / kg, twice a day) was 1.56 mm, the mean ear thickness was 0.5 mm, and the mean score was 3.5 points. Compared with the G2 negative control group (mean back bilayer skin thickness was 2.64 mm, the mean ear thickness was 0.79 mm, and the mean AD-SI score was 10.67 points), the inflammatory thickening of the back skin was significantly inhibited and the AD symptoms were significantly improved in the G7 group, with the inhibition rate of back skin thickness being 53.73% and the inhibition rate of ear thickness being 50%, both of which were statistically significant (P<0.01).

[0172] On the 10th day of treatment, the mean ear thickness of the G6 group treated with crystalline form A (10 mg / kg, twice a day) was 0.54 mm, and the mean AD-SI score was 4.67 points. Compared with the G2 negative control group (mean ear thickness was 0.79 mm, and the mean AD-SI score was 10.67 points), the inflammatory thickening of the ear was significantly inhibited and the AD symptoms were significantly improved in the G6 group, with the inhibition rate of the ear thickness being 43.1%, both of which were statistically significant (P<0.05). In the group treated with crystalline form A (10 mg / kg, twice a day), the mean back two-layer skin thickness was 2.23 mm, and compared with the G2 negative control group, the inflammatory thickening of the back skin was inhibited, with the inhibition rate being 20.4%.

[0173] Example B: Pharmacodynamic Effects in Animal Models of Psoriasis 1. Experimental materials (1) Experimental animals and breeding methods Seventy-five C57 / BL 6J mice, female, 7-8 weeks old, weighing 18g-20g. The animals were purchased from Zhejiang Weitong Lihua Laboratory Animal Technology Co., Ltd. (SCXK(Zhejiang)2019~0001), the experimental animal production qualification certificate number was 20210107Abzz0619000247, and the experimental animal use permit number was SYXK(Shanghai)2020~0001 (Weiya Biotechnology (Shanghai) Co., Ltd.).

[0174] All mice were housed in an SPF-grade IVC constant temperature and pressure system and maintained at a constant temperature. The temperature was 20°C-26°C, the humidity was 40%-70%, and the light cycle was 12 hours light and 12 hours dark. Three to five mice were housed in each cage, the cage size was 325mm × 210mm × 180mm, and the bedding in the cage was changed twice a week. Throughout the entire course of the experiment, all experimental mice had free access to food and drink, and all the feed and water were autoclaved and changed twice a week.

[0175] (2) Test sample a. Tofacitinib, free base, purity 98%, total amount 100mg, storage temperature 4℃ b. Crystal form A, purity 99.7%, total amount 200mg, storage temperature 4℃

[0176] 2. Experimental steps and methods Modeling and administration method: A hair removal cream was used to remove hair from the back of each animal in an area of ​​approximately 2 cm x 3 cm. The application time of the hair removal cream was controlled within 2 minutes. After that, the hair removal site was washed with warm water, and the animal's hair was dried with a hair dryer immediately after washing the hair removal agent, and the animal was placed on a 37°C constant temperature electric blanket for 1 to 2 hours. After the animal behaved normally and freely, it was normally housed in a breeding cage for 1 day to recover (if the animal's skin was red, swollen, and damaged after hair removal, the animal was removed). The next day, 54 animals with normal skin were selected and randomly divided into groups according to weight, with 9 animals in each group, for a total of 6 groups. Each animal in groups G2 to G6 was uniformly applied with 60 mg (60 μL) of 5 wt% imiquimod cream (Aldara) on its back every day for 7 consecutive days. The administration route, dosage, and grouping of the psoriasis model efficacy experiment are shown in Table 13.

[0177] [Table 13]

[0178] The preparation method of the test drugs is shown in Table 14.

[0179] [Table 14]

[0180] 3. Experimental observation Throughout the course of the study, all use and observation of laboratory animals was conducted in accordance with the relevant standards for the use and care of AAALAC animals.

[0181] 4. Evaluation indicators Skin thickness (2 layers): The thickness of the 2 layers of skin on the back was measured using a caliper before administration and modeling, and on the 1st, 3rd, 5th, and 7th days after administration.

[0182] PASI score: The symptom score was based on the clinical PASI score standard. Three indicators, erythema, scaling, and degree of thickening, were scored for a total of 12 points. The score standard was as follows:

[0183] Erythema: Score 0: no erythema, score 1: mild and light pink, score 2: moderate and red, score 3: significant and deep red, score 4: very significant and very deep red.

[0184] Scales: Score 0: no scale; Score 1: mild and some scale on the epidermis, but mainly minor; Score 2: moderate and most of the skin surface is completely or incompletely covered with sheet-like scales; Score 3: noticeable and almost the entire skin is covered with scales, with the scales being relatively thick and layered; Score 4: very noticeable and the entire skin is covered with scales, with the scales being thick and layered.

[0185] Degree of plaque thickening: Score 0: no thickening, same as normal skin; Score 1: mild and slightly higher than normal skin surface; Score 2: moderate and moderately elevated, plaque edges are rounded or sloping; Score 3: noticeable and plaque thickening, obvious swelling; Score 4: very noticeable and very thickening, very obvious swelling. Inhibition rate of skin thickening (%)=1-[(skin thickness of treatment group on day 7-skin thickness of blank control group on day 7) / (skin thickness of negative control group on day 7-skin thickness of blank control group on day 7)]%.

[0186] After the experiment was completed, the back skin of the mice was dissected, isolated, and fixed in formalin for storage.

[0187] 5. End of experiment After 7 days of treatment, the animals were euthanized. The dorsal skin of the mice was dissected, isolated, and fixed in formalin for storage.

[0188] 6. Data analysis All data were expressed as Mean ± SEM. Data were subjected to normal distribution test and homogeneity of variance test using statistical analysis software SPSS23.0. Depending on the results, homogeneity of variance test was selected, and one-way analysis of variance method was selected depending on the results. * P<0.05 was considered to indicate a statistically significant difference.

[0189] 7. Experimental results (1) Effect of the test drug on skin thickness The changes in average skin thickness and the inhibitory effect of each group on the 7th day of treatment are shown in Table 15, Table 16 and Figure 24. Figure 24 is a graph showing the changes in skin thickness of each group during the treatment period.

[0190] [Table 15]

[0191] remarks: * P < 0.05, ** P < 0.01, *** P<0.001 compared with the G2 negative control group.

[0192] [Table 16]

[0193] remarks: * P < 0.05, ** P < 0.01, *** P<0.001 compared with the G2 negative control group.

[0194] (2) Effect of the test drug on the psoriasis severity (PASI) score in psoriasis model animals The change in PASI score for each group (n=9) on the 7th day of treatment is shown in Table 17 and Figure 25. Figure 25 is a graph showing the change in PASI score for each group during the treatment period.

[0195] [Table 17]

[0196] remarks: * P < 0.05, ** P < 0.01, *** P<0.001 compared with the G2 negative control group.

[0197] Results Analysis: On the 7th day of treatment, G treated with crystalline form A (0.5 mg / kg, twice daily) In group 4, the average PASI score was 6.1 points, and compared with the G2 negative control group, the symptoms of psoriasis were significantly improved, with a statistically significant difference (P<0.05).

[0198] On the 7th day of treatment, in group G5 treated with crystalline form A (1.5 mg / kg, twice a day) and group G6 treated with crystalline form A (5 mg / kg, twice a day), the mean back bilayer skin thickness was 1.15 mm and 1.03 mm, respectively, and the mean PASI scores were 4.9 and 3.6, respectively. Compared with the G2 negative control group, inflammatory thickening of the back skin was significantly inhibited, and the symptoms of psoriasis were significantly improved. The inhibition rates of back skin thickening were 56.4% and 71.8%, respectively, and all were statistically significant (P<0.001).

[0199] As can be seen from the above, the novel crystalline form of the compound (R)-2-(1-(2-(1-hydroxyethyl)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)piperidin-4-yl)acetonitrile free base provided by the present invention has good stability, high solubility, and the effect of inhibiting inflammatory thickening of the back skin and inflammatory thickening of the ear of mice, and can effectively improve the onset of atopic dermatitis and psoriasis. In addition, the preparation method of the novel crystalline form is simple and reproducible, and can meet the requirements for large-scale industrial production.

[0200] Since the embodiments in this specification are described in relation to each other, identical or similar parts between the embodiments can be referred to each other. In each embodiment, the differences from other embodiments will be mainly described.

[0201] The above description is merely a preferred embodiment of the present application, and is not intended to limit the present application. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principle of the present application should be included in the protection scope of the present application.

Claims

1. Crystalline form A of compound of formula (I), [Formula 1] The powder X-ray diffraction spectrum is characterized by characteristic peaks at 2θ angles of 8.6°±0.2°, 9.8°±0.2°, 10.7°±0.2°, 11.2°±0.2°, 12.3°±0.2°, 12.9°±0.2°, 16.0°±0.2°, and 19.0°±0.2°.

2. 2. The crystalline form A of claim 1, characterized in that the powder X-ray diffraction spectrum has characteristic peaks at 2θ angles of 8.6°±0.2°, 9.8°±0.2°, 10.7°±0.2°, 11.2°±0.2°, 12.3°±0.2°, 12.9°±0.2°, 16.0°±0.2°, 17.0°±0.2°, 17.4°±0.2°, 17.8°±0.2°, 19.0°±0.2°, 19.9°±0.2°, and 21.2°±0.2°.

3. The crystalline form A according to claim 1 or 2, characterized in that the powder X-ray diffraction spectrum is essentially as shown in Table 1.

4. The crystalline form A according to any one of claims 1 to 3, characterized in that the powder X-ray diffraction spectrum is essentially as shown in Figure 2.

5. Crystalline form Q of compound of formula (I), [Case 2] The powder X-ray diffraction spectrum is characterized by characteristic peaks at 2θ angles of 8.5°±0.2°, 14.5°±0.2°, 15.0°±0.2°, 16.8°±0.2°, 19.4°±0.2°, 23.6°±0.2°, 24.8°±0.2°, 26.3°±0.2°, and 27.4°±0.2°.

6. The powder X-ray diffraction spectrum was 8.5°±0.2°, 14.5°±0.2°, 15.0°±0.2°, 15.8°±0.2°, 16.8°±0.2°, 18.8°±0.2°, 19. The crystalline form Q of claim 5, characterized in that it has characteristic peaks at 2θ angles of 2.4°±0.2°, 20.1°±0.2°, 23.6°±0.2°, 24.8°±0.2°, 26.3°±0.2°, and 27.4°±0.2°.

7. The crystalline form Q according to claim 5 or 6, characterized in that the powder X-ray diffraction spectrum is essentially as shown in FIG.

8. A pharmaceutical composition comprising a therapeutically effective amount of crystalline form A according to any one of claims 1 to 4, crystalline form Q according to any one of claims 5 to 7 or a mixture thereof, and a pharma- ceutically acceptable carrier, diluent or excipient.

9. A pharmaceutical composition for animals, comprising a therapeutically effective amount of crystalline form A according to any one of claims 1 to 4, crystalline form Q according to any one of claims 5 to 7, or a mixture thereof, and a pharma- ceutically acceptable carrier, diluent or excipient.

10. A process for preparing crystalline form A according to any one of claims 1 to 4, comprising the steps of: The method of claim 1, further comprising: dissolving the compound of formula (I) in ethanol until it becomes clear, concentrating the solution, stirring the concentrate to precipitate a solid, filtering and drying the solid to obtain the crystalline form A.

11. Use of crystalline form A according to any one of claims 1 to 4, crystalline form Q according to any one of claims 5 to 7, a pharmaceutical composition according to claim 8, or a veterinary pharmaceutical composition according to claim 9 in the preparation of a medicament.

12. 12. Use according to claim 11, characterized in that the medicinal product is for treating, preventing and / or delaying allergic reactions, allergic dermatitis, atopic dermatitis, eczema, pruritus or psoriasis.

13. 13. The use according to claim 12, characterized in that the medicament is for treating, preventing and / or delaying allergic reactions, allergic dermatitis, atopic dermatitis, eczema, pruritus or psoriasis in a mammal.

14. The use according to claim 13, characterized in that the mammal comprises a companion animal.

15. The use according to claim 13 or 14, characterized in that the mammal comprises a domestic animal.

16. The use according to any one of claims 11 to 15, characterized in that the medicament is for the treatment of a disease mediated by a JAK kinase.

17. 1. A method for treating and / or preventing a disease, comprising: The method comprises administering a therapeutically effective amount of the crystalline form of any one of claims 1 to 7, the pharmaceutical composition of claim 8, or the veterinary pharmaceutical composition of claim 9 to a subject mammal.

18. 18. The method of claim 17, wherein the therapeutically effective amount is between 0.01 mg / kg body weight / day and 100 mg / kg body weight / day.

19. The method according to claim 17 or 18, characterized in that the therapeutically effective amount is between 0.1 mg / kg body weight / day and 30 mg / kg body weight / day.

20. The method according to any one of claims 17 to 19, characterized in that the disease is mediated by a JAK kinase.

21. The method according to any one of claims 17 to 20, wherein the mammal comprises a companion animal.

22. The method according to any one of claims 17 to 21, characterized in that the mammal comprises a domestic animal.

23. The method according to any one of claims 17 to 22, characterized in that it is administered orally, parenterally or topically.

Citation Information

Patent Citations

  • Cyano-substituted cyclic hydrazine derivative and application thereof

    WO2021051899A1